The COVID-19 pandemic has elevated the world's attention to olfactory impairment (OI). As a cardinal symptom of the many early variants of the SARS-CoV-2 virus, we have never seen such global attention toward one of our most important senses. Although the prevalence of OI has increased dramatically with COVID-19, OIs have long been a significant health concern. Prior to the COVID-19 pandemic, the median length of time from onset of OI to evaluation by a clinician was 13 months, with many individuals waiting up to 3 years before seeking evaluation. During that time, patients did not receive treatment or counseling, compounding the potential associations of OI with patient health. 1 Whether on its own or as a shared symptom of other sinus or neurologic disorders, the negative association of OI with quality of life has been well documented. 2 Its association with degenerative neurologic conditions, such as Parkinson disease, has also been shown. 2 Clinicians who treat OI will often counsel patients on adjusting protocols to ensure that safety precautions are taken as they adjust to OI, so as to decrease the risk of toxic exposures. However, to our knowledge, almost no data have been used to explore the association of this sensory disorder with mortality. In this issue of JAMA Otolaryngology-Head & Neck Surgery, Pang et al 3 have explored the association of OI with mortality in a meta-analysis of 21 601 individuals across 11 studies of OI. They found a 52% higher risk of all-cause mortality among individuals with objective smell loss. We will explore their methods and what questions remain regarding OI's association with mortality.Pang et al 3 followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Metaanalysis of Observational Studies in Epidemiology (MOOSE) guidelines to perform a systematic review of publications on OI from PubMed, Embase, and the Cochrane Library until August 31, 2021. In their analysis, they excluded publications that studied COVID-19-related OI. This exclusion was important because the COVID-19-related severity and mortality would likely bias the results. In addition, the longterm effects of COVID-19-related OI are still being elucidated. Of 1088 studies, 11 were ultimately included, and 9 studies were appropriate for the meta-analysis. The authors identified a pooled hazard ratio of 1.52 for all-cause mortality among patients with OI.The article by Pang et al 3 is a well-designed metaanalysis of the existing literature. However, the limitations should give readers caution in interpreting the results and should help researchers with future studies into OI's effects. First, participants who present to a specialist for evaluation of OI are more likely to have persistent and bothersome dysfunction, creating selection bias. There are also questions